@FierceMedDev: Teleflex's vascular system gains pivotal FDA clearance--the product comes from a previous M&A deal. More | Follow @FierceMedDev
@MarkHFierce: Mela Sciences' 2013 financials show how tough a relaunch of its skin cancer Dx tool will be. Story | Follow @MarkHFierce
@MichaelGFierce: SynapDx, Broad Institute align to make autism Dx with next-gen sequencing. Item | Follow @MichaelGFierce
@EmilyWFierce: Evidence of world's oldest case of metastatic cancer found in a skeleton in the Sudan. Article | Follow @EmilyWFierce
> Medtronic ($MDT) will market Itamar Medical's sleep apnea diagnostic products to atrial fibrillation patients in the U.S. Story
> NeuroMetrix ($NURO) of Waltham, MA, said it is rolling out the first shipments of its second-generation wearable pain management device. Release
> CeloNova BioSciences said it won FDA approval to begin an IDE trial for its new coronary stent system, which is designed to use a nano-coating technology that helps the artery heal faster and reduce the need for long-term blood-thinning medication. Release
> Digirad, a Georgia maker of imaging devices, snatched up Telerhythmics, a provider of 24-hour cardiac monitoring services, in a deal worth at least $3.6 million. Story
> CorTechs Labs nailed down a new Series B investment intended to accelerate the development of its image analysis medical software and also boost sales/marketing efforts. Release
Biotech News
@FierceBiotech: AstraZeneca signs up for MD Anderson's 'moon-shot' immuno-oncology project. More | Follow @FierceBiotech
@JohnCFierce: Upbeat review of failed PhII DMD trial earns Prosensa a big boost to shares. News | Follow @JohnCFierce
@DamianFierce: A quarter of European doctors can't define biosimilars. Story via Bloomberg. | Follow @DamianFierce
@EmilyMFierce: Snails and quails in today's issue of FierceBiotech Research. | Follow @EmilyMFierce
> Meet RestorGenex, a biotech mosaic from Celgene founder Barer. News
> Eager biotechs eye $133M in IPOs as a frenzied quarter closes. Article
Pharma News
@FiercePharma: Best-read special report over the weekend: Top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma
@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @TracyStaton
@EricPFierce: New purification plant is part of Novo Nordisk 's $3.7B R&D push. News | Follow @EricPFierce
@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce
> Pfizer sues India's Torrent in latest bid to fend off generic Viagra. News
> Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales. More
> New incontinence data could give Ipsen's Dysport a path to lucrative urology use. Story
Biotech Research News
> Capturing leukemic stem cells may help propel new drug discovery. More
> Study: Chickens, quails are likely to blame for spread of H7N9. Piece
> Drug derived from snail venom could treat chronic pain with fewer side effects. Article
> Compound stops formation of toxic peptides in mice with Alzheimer's. More
> NIH cuts, sequestration hampering cancer research. Story
> Stem cell therapy improves tendon healing in preclinical study. Item
Pharma Manufacturing News
> Japan's Eisai intends to nearly triple production to 2 billion tablets at its plant in Vizag, India. Report
> The FDA has added two Chinese drug manufacturing facilities to its list of banned plants. Alerts
> India's Supreme Court ruled in favor of a public interest investigation into whether Ranbaxy Laboratories supplied adulterated drugs in the country. Report
> Ranbaxy Laboratories insists the drugs it sells in India are safe and effective. Story
> Optel Visions is expanding its inspection systems offerings. Release